In our study, the overall rate of CRS events was 60.4% with a higher rate of 68.1% for BsAbs that target BCMA and a lower rate of 55.7% for BsAbs that target receptors other than BCMA on malignant cells. The gene discussed is TNFRSF17; the disease is congenital rubella syndrome.